You don't see full trials of screening very often, but here are two mega trials.
First up: cancer of the ovary. It is one of the commonest fatal cancers in women, often presents late, easier to treat if caught early, the screening test (blood sample and ultrasound, albeit transvaginal) is simple: seems like a no-brainer. Gynaecologists, understandably distressed by seeing so many cases present late, argue long and loud for screening. But...
It is a good write-up, worth reading carefully. Note also that 78 000 women were randomised - that's why you don't see full trials of screening very often. Also, once you've done a huge trial like this you probably won't want to fund a subtly different one (e.g. different screening interval, newer technology etc etc).
Next: lung cancer. An even bigger mega trial. Screening trials for lung cancer forty years ago were disappointing. With the technology then available, by the time you could see the cancer it was too late. But nowadays imaging is much better. Useful to use the PICO framework for this paper: Population, Intervention, Comparator, Outcome. Note the target population and the comparator. All cause deaths is an important outcome to check because of course all that radiation from CT scans could perhaps have caused a few extra leukaemias etc.
Unusually but entirely correctly the authors emphasise the importance of cost-effectiveness studies now the main result is in (they have these in hand).